
A Medicine Company | Eli Lilly and Company
Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.
Eli Lilly and Company - Wikipedia
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries.
Eli Lilly and Company (LLY) - Yahoo Finance
Eli Lilly, based in Indianapolis, develops and manufactures therapies to treat pain, diabetes, cancer, and neurodegenerative diseases. The shares are a component of the S&P 500 Index.
Available Medications - Lilly Cares
Frequently Asked Questions (FAQ) What if my medication is not listed or I don't qualify for Lilly Cares?
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of ...
Feb 12, 2026 · Eli Lilly had $1.5 billion worth of pre-launch inventory of its experimental oral weight-loss drug, a filing showed on Thursday, ahead of an expected decision by the U.S. Food and Drug ...
Online Pharmacy Service Options for Select Lilly Medicines | LillyDirect®
Get authentic Lilly medicines, if prescribed, with the convenience of home delivery or pickup at a retail location near you (pickup available for select medicines).
1 Reason I'd Buy Eli Lilly Stock and Never Sell | The Motley Fool
3 days ago · Eli Lilly has been busy building its drug pipeline for the future. The company currently sells the world's best-selling drug. It just bought Orna Therapeutics, an innovative drugmaker. A robust ...
Lilly to acquire Orna Therapeutics to advance cell therapies
Feb 9, 2026 · /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today...
Find Your Career with Eli Lilly | Lilly Careers
Find your place at Lilly with Lilly Careers. For more than a century, we have united caring with discovery to make life better, join us today.
Eli Lilly (LLY) earnings Q4 2025 - CNBC
Feb 4, 2026 · Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.